Abstract
Bress et al1 estimated the deaths prevented and excess serious adverse events incurred if the SPRINT (Systolic Blood Pressure Intervention Trial) intensive systolic blood pressure (SBP) treatment goal were implemented in all eligible US adults and observed that, if fully implemented in eligible US adults, intensive SBP treatment could prevent ≈107 500 deaths per year; however, a consequence of this treatment strategy could be an increase in serious adverse events. The best therapeutic target of SBP has been …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
